Bayer HealthCare AG, Global Drug Discovery, Medicinal Chemistry, Wuppertal, Germany.
Drug Discov Today. 2011 Jun;16(11-12):530-8. doi: 10.1016/j.drudis.2011.04.008. Epub 2011 Apr 30.
The number of solved X-ray structures of proteins relevant for ADMET processes of drug molecules has increased remarkably over recent years. In principle, this development offers the possibility to complement the quantitative structure-property relationship (QSPR)-dominated repertoire of in silico ADMET methods with protein-structure-based approaches. However, the complex nature and the weak nonspecific ligand-binding properties of ADMET proteins take structural biology methods and current docking programs to the limit. In this review we discuss the utility of protein-structure-based design and docking approaches aimed at overcoming issues related to plasma protein binding, active transport via P-glycoprotein, hERG channel mediated cardiotoxicity and cytochrome P450 inhibition, metabolism and induction.
近年来,与药物分子 ADMET 过程相关的已解决的蛋白质 X 射线结构数量显著增加。原则上,这一发展为定量构效关系(QSAR)主导的计算 ADMET 方法提供了用基于蛋白质结构的方法进行补充的可能性。然而,ADMET 蛋白的复杂性质和较弱的非特异性配体结合特性使得结构生物学方法和当前的对接程序达到了极限。在这篇综述中,我们讨论了基于蛋白质结构的设计和对接方法的实用性,旨在克服与血浆蛋白结合、通过 P-糖蛋白主动转运、hERG 通道介导的心脏毒性和细胞色素 P450 抑制、代谢和诱导相关的问题。